Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 17/20 | 1.00 |
| ▸ | STAT5B | P51692 | 5/20 | 1.00 |
| ▸ | STAT1 | P42224 | 3/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.70 |
| ▸ | PTPRS | Q13332 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615046 | 1.00 | STAT3 (1.00) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL8282956 | 0.89 | STAT3 (1.00) | STAT3STAT5BSTAT1 | |
| SCHEMBL10243263 | 0.89 | STAT3 (1.00) | STAT3STAT5BSTAT1 | |
| SCHEMBL29374125 | 0.89 | STAT3 (1.00) | STAT3STAT5BSTAT1 | |
| SCHEMBL16130770 | 0.89 | STAT3 (0.92) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL17308734 | 0.88 | STAT5B (0.80) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL16787373 | 0.87 | STAT3 (0.78) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL10243280 | 0.87 | STAT3 (0.84) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL17308730 | 0.86 | STAT5B (0.83) | STAT3STAT5BSTAT1PTPN2PTPN1 | |
| SCHEMBL18719967 | 0.85 | STAT5B (0.76) | STAT3STAT5BSTAT1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205569-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF AND TREATMENT FOR ECTOPIC CALCIFICATION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10473669-B2 | Methods for treating inflammatory bowel disease | NOGRA PHARMA LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| EP-3355896-A2 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | Nogra Pharma Limited (IE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180180630-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| EP-3237018-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | Celgene Alpine Investment Company II, LLC (BM) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017055611-A9 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2017-07-27 | — | — | WO | disclosed |
| WO-2016105516-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | UNIVERSITY OF TORONTO MISSISSAUGA (CA) | 2013-08-29 | — | — | US | disclosed |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | UNIVERSITY OF TORONTO MISSISSAUGA (CA) | 2013-08-29 | — | — | US | disclosed |
| WO-2012018868-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | SMAD3, SMAD2, SOST | STAT3 327/4885STAT5B 1068/4885STAT1 86/4885 |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | STAT3 1/4885STAT5B 5/4885STAT1 2/4885 |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | STAT3 1/4885STAT5B 5/4885STAT1 2/4885 |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | SMAD3, SMAD2, SOST | STAT3 207/4885STAT5B 455/4885STAT1 41/4885 |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | STAT3, STAT1, STAT4 | STAT3 1/4885STAT5B 5/4885STAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.